Market Overview

Analysts Come Out Bullish On Radius Health, Shares Rally

Related RDUS
Radius Health Announces Positive Phase 3 Data from ACTIVExtend Trial at ASBMR
Morning Market Gainers
Radius (RDUS) Reports Positive Data on Osteoporosis Drug (Zacks)

Early Wednesday morning, four analyst firms issued notes initiating bullish coverage on Radius Health (NASDAQ: RDUS).

Shares of Radius Health have shot up nearly six percent on the news. The firms respective ratings and price targets are listed below.

  • Canaccord Genuity - Buy, $21
  • Cowen & Company - Outperform, N/A
  • Cantor Fitzgerald - Buy, $20
  • Jefferies - Buy, $17

The average of these price targets is $19.33, which represents 53 percent upside to last check price of $12.62.

Latest Ratings for RDUS

Sep 2015Canaccord GenuityMaintainsBuy
Aug 2015Deutsche BankInitiates Coverage onBuy
Aug 2015Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for RDUS
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Cantor FitzgeraldAnalyst Color Price Target Initiation Hot Analyst Ratings Movers


Related Articles (RDUS)

Get Benzinga's Newsletters